Arax Advisory Partners’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$45.6K Sell
49,522
-5,477
-10% -$5.89K ﹤0.01% 3400
2026
Q2
$62.7K Buy
54,999
+15,897
+41% +$18.9K ﹤0.01% 3089
2026
Q1
$54.4K Buy
39,102
+9
+0% +$12 ﹤0.01% 1661
2025
Q4
$62.9K Sell
39,093
-507
-1% -$1.06K ﹤0.01% 1504
2025
Q3
$108K Buy
39,600
+14,783
+60% +$49.2K ﹤0.01% 1507
2025
Q2
$90.3K Hold
24,817
– – ﹤0.01% 977
2025
Q1
$47.6K Buy
24,817
+11,117
+81% +$22.7K ﹤0.01% 961
2024
Q4
$26K Buy
+13,700
New +$23.8K ﹤0.01% 1110

Other funds holding AKBA

Arax Advisory Partners's AKBA Position: Q3 2026 in Review

Arax Advisory Partners reduced its Akebia Therapeutics (AKBA) stake by 10% in Q3 2026, selling an estimated $5.89K and leaving 49,522 shares worth $45.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3400.

Arax Advisory Partners first reported a position in AKBA in Q4 2024 and has held it in 8 quarters since. The position peaked at $108K in Q3 2025. 120 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Arax Advisory Partners held 49,522 shares of Akebia Therapeutics worth $45.6K as of Q3 2026.
  • Arax Advisory Partners sold 5,477 Akebia Therapeutics shares in Q3 2026, an estimated $5.89K.
  • Akebia Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #3400 holding.
  • Arax Advisory Partners first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Arax Advisory Partners's Akebia Therapeutics position peaked at $108K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.